S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Kymera Therapeutics, Inc. (KYMR)
Chart Events
Performance Outlook
| Previous Close | 14.89 |
| Open | 15.25 |
| Bid | 12.26 x 2200 |
| Ask | 14.78 x 1300 |
| Day's Range | 13.64 - 15.42 |
| 52 Week Range | 13.62 - 69.12 |
| Volume | |
| Avg. Volume | 607,603 |
| Market Cap | 760.015M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.71 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 68.25 |
- GlobeNewswire
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022, taking place from May
- TipRanks
Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse
On Wall Street, some things never change. High inflation or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable r
- GlobeNewswire
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support further exploration of STAT3 degraders in Th17-driven autoimmune indications WATERTOWN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted pr
